WebIonis Pharmaceuticals Inc is expected to show a decrease in its fourth quarter earnings to -92 cents per share according to the mean Refinitiv 20 February 2024 01:59 p.m. All figures in US dollars. WebAnalyst Report: Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical …
IONS Stock Price and Chart — NASDAQ:IONS — …
Web26 jul. 2024 · About Ionis Pharmaceuticals, Inc. For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of … Web23 mrt. 2024 · Ionis Pharmaceuticals Inc. Follow. 9 results. Healthcare & Pharmaceuticals. category. US FDA panel backs accelerated approval for Biogen's ALS … chin heng group
News IONIS PHARMACEUTICALS Stock Price Today - Insider
WebIonis Pharmaceuticals, Inc. operates as a biotechnology company. The Company researches in RNA-targeted drug discovery and development that focuses on drugs for … Web12 apr. 2024 · 10 analysts have issued 1 year price objectives for Ionis Pharmaceuticals' stock. Their IONS share price forecasts range from $27.00 to $67.00. On average, they … Web11 feb. 2024 · CARLSBAD, Calif., Feb. 11, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that the European Medicines Agency (EMA) has granted orphan drug designation to ION373 for the treatment of people with Alexander disease, a severe, progressive and debilitating … chin heng furnishing centre